Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced He
 

Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says: "This study suggests that patients with HER2 positive advanced breast cancer who are no longer responding to Herceptin or chemotherapy may benefit from the combined Herceptin and DM1 treatment. Whilst many patients responded to the treatment in this trial, further larger studies will be needed to assess the full benefits.

More...